B

BioPlus Co Ltd
KOSDAQ:099430

Watchlist Manager
BioPlus Co Ltd
KOSDAQ:099430
Watchlist
Price: 7 700 KRW 1.99% Market Closed
Market Cap: 433.5B KRW
Have any thoughts about
BioPlus Co Ltd?
Write Note
BioPlus Co Ltd
/
Cash Flow Statement
/
Net Issuance of Common Stock

BioPlus Co Ltd
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioPlus Co Ltd
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
B
BioPlus Co Ltd
KOSDAQ:099430
Net Issuance of Common Stock
-₩4.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SD Biosensor Inc
KRX:137310
Net Issuance of Common Stock
₩227.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
HLB Inc
KOSDAQ:028300
Net Issuance of Common Stock
₩16B
CAGR 3-Years
-30%
CAGR 5-Years
-12%
CAGR 10-Years
24%
T
T&L Co Ltd
KOSDAQ:340570
Net Issuance of Common Stock
-₩35.7k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
H
Humasis Co Ltd
KOSDAQ:205470
Net Issuance of Common Stock
-₩27B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Interojo Co Ltd
KOSDAQ:119610
Net Issuance of Common Stock
₩36.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BioPlus Co Ltd
Glance View

Market Cap
433.5B KRW
Industry
Health Care

BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.

Intrinsic Value
15 791.58 KRW
Undervaluation 51%
Intrinsic Value
Price
B
What is Intrinsic Value?

See Also

What is BioPlus Co Ltd's Net Issuance of Common Stock?
Net Issuance of Common Stock
-4.5B KRW

Based on the financial report for Dec 31, 2023, BioPlus Co Ltd's Net Issuance of Common Stock amounts to -4.5B KRW.

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.